{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:01:31Z","timestamp":1740106891965,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T00:00:00Z","timestamp":1706918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T00:00:00Z","timestamp":1706918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Lymphoma Research Foundation of Chinese Anticancer Associatio","award":["CORP-117"],"award-info":[{"award-number":["CORP-117"]}]},{"name":"National Natural Science Foundation of China Youth Fun","award":["82000204"],"award-info":[{"award-number":["82000204"]}]},{"name":"Science and technology project of Henan Provinc","award":["232102311114"],"award-info":[{"award-number":["232102311114"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00277-024-05648-5","type":"journal-article","created":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T03:01:56Z","timestamp":1706929316000},"page":"2003-2012","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Modified R-BAC plus BTK inhibitor regimen in newly diagnosed young patients with mantle cell lymphoma: a real-world retrospective study"],"prefix":"10.1007","volume":"103","author":[{"given":"Wenqi","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinmiao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zurui","family":"Geng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5768-4840","authenticated-orcid":false,"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,3]]},"reference":[{"key":"5648_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.770988","volume":"11","author":"M Wu","year":"2021","unstructured":"Wu M, Li Y, Huang H et al (2021) Initial treatment patterns and survival outcomes of mantle cell lymphoma patients managed at Chinese Academic Centers in the Rituximab Era: A Real-World Study. Front Oncol 11:770988","journal-title":"Front Oncol"},{"key":"5648_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103212","volume":"158","author":"N Monga","year":"2021","unstructured":"Monga N, Tam C, Garside J et al (2021) Clinical efficacy and safety of first-line treatments in patients with mantle cell lymphoma: a systematic literature review. Crit Rev Oncol Hematol 158:103212","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10044","key":"5648_CR3","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"O Hermine","year":"2016","unstructured":"Hermine O, Hoster E, Walewski J et al (2016) Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet 388(10044):565\u2013575","journal-title":"Lancet"},{"issue":"1","key":"5648_CR4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","volume":"121","author":"R Delarue","year":"2013","unstructured":"Delarue R, Haioun C, Ribrag V et al (2013) CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. Blood 121(1):48\u201353","journal-title":"Blood"},{"issue":"1","key":"5648_CR5","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.bcmd.2011.09.007","volume":"48","author":"C Visco","year":"2012","unstructured":"Visco C, Castegnaro S, Chieregato K et al (2012) The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines. Blood Cells Mol Dis 48(1):68\u201375","journal-title":"Blood Cells Mol Dis"},{"issue":"11","key":"5648_CR6","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1200\/JCO.2012.45.9842","volume":"31","author":"C Visco","year":"2013","unstructured":"Visco C, Finotto S, Zambello R et al (2013) Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol 31(11):1442\u20131449","journal-title":"J Clin Oncol"},{"issue":"1","key":"5648_CR7","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S2352-3026(16)30185-5","volume":"4","author":"C Visco","year":"2017","unstructured":"Visco C, Chiappella A, Nassi L et al (2017) Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. Lancet Haematol 4(1):e15\u2013e23","journal-title":"Lancet Haematol"},{"issue":"1","key":"5648_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40364-022-00357-5","volume":"10","author":"J Zhang","year":"2022","unstructured":"Zhang J, Lu X, Li J et al (2022) Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma. Biomark Res 10(1):17","journal-title":"Biomark Res"},{"issue":"20","key":"5648_CR9","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375\u20132390","journal-title":"Blood"},{"issue":"27","key":"5648_CR10","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059\u20133068","journal-title":"J Clin Oncol"},{"key":"5648_CR11","doi-asserted-by":"crossref","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L et al (2014) Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 32(27):3048\u201358","DOI":"10.1200\/JCO.2013.53.5229"},{"issue":"2","key":"5648_CR12","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","volume":"111","author":"E Hoster","year":"2008","unstructured":"Hoster E, Dreyling M, Klapper W et al (2008) A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111(2):558\u2013565","journal-title":"Blood"},{"issue":"12","key":"5648_CR13","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","volume":"34","author":"E Hoster","year":"2016","unstructured":"Hoster E, Rosenwald A, Berger F et al (2016) Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. J Clin Oncol 34(12):1386\u20131394","journal-title":"J Clin Oncol"},{"issue":"5","key":"5648_CR14","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579\u2013586","journal-title":"J Clin Oncol"},{"issue":"1","key":"5648_CR15","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1016\/j.clml.2017.11.002","volume":"18","author":"Y Sawalha","year":"2018","unstructured":"Sawalha Y, Hill BT, Rybicki LA et al (2018) Efficacy of standard dose R-CHOP alternating With R-HDAC followed by autologous hematopoietic cell transplantation as initial therapy of mantle cell lymphoma, a single-institution experience. Clin Lymphoma Myeloma Leuk 18(1):e95\u2013e102","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"13","key":"5648_CR16","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","volume":"377","author":"S le Gouill","year":"2017","unstructured":"le Gouill S, Thieblemont C, Oberic L et al (2017) Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med 377(13):1250\u20131260","journal-title":"N Engl J Med"},{"issue":"9","key":"5648_CR17","doi-asserted-by":"publisher","first-page":"e617","DOI":"10.1016\/S2352-3026(21)00237-4","volume":"8","author":"A Chiappella","year":"2021","unstructured":"Chiappella A, Ladetto M (2021) The role of autologous haematopoietic stem-cell transplantation in mantle cell lymphoma. Lancet Haematol 8(9):e617\u2013e619","journal-title":"Lancet Haematol"},{"issue":"6","key":"5648_CR18","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P et al (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369(6):507\u2013516","journal-title":"N Engl J Med"},{"issue":"1","key":"5648_CR19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","volume":"17","author":"ML Wang","year":"2016","unstructured":"Wang ML, Lee H, Chuang H et al (2016) Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol 17(1):48\u201356","journal-title":"Lancet Oncol"},{"issue":"26","key":"5648_CR20","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","volume":"386","author":"ML Wang","year":"2022","unstructured":"Wang ML, Jurczak W, Jerkeman M et al (2022) Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med 386(26):2482\u20132494","journal-title":"N Engl J Med"},{"issue":"23","key":"5648_CR21","doi-asserted-by":"publisher","first-page":"6089","DOI":"10.3390\/cancers13236089","volume":"13","author":"G Bega","year":"2021","unstructured":"Bega G, Olivieri J, Riva M et al (2021) Rituximab and bendamustine (BR) compared with rituximab, bendamustine, and cytarabine (R-BAC) in previously untreated elderly patients with mantle cell lymphoma. Cancers (Basel) 13(23):6089","journal-title":"Cancers (Basel)"},{"issue":"4","key":"5648_CR22","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bjh.16416","volume":"189","author":"R McCulloch","year":"2020","unstructured":"McCulloch R, Visco C, Eyre TA et al (2020) Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy. Br J Haematol 189(4):684\u2013688","journal-title":"Br J Haematol"},{"key":"5648_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood-2022-163018","volume":"140","author":"M Dreyling","year":"2022","unstructured":"Dreyling M, Doorduijn JK, Gine E et al (2022) Efficacy and safety of ibrutinib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: results from the randomized triangle trial by the European MCL Network. Blood 140:1\u20133","journal-title":"Blood"},{"issue":"5","key":"5648_CR24","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1182\/bloodadvances.2022007241","volume":"7","author":"S Ekberg","year":"2023","unstructured":"Ekberg S, Smedby KE, Albertsson-Lindblad A et al (2023) Late effects in patients with mantle cell lymphoma treated with or without autologous stem cell transplantation. Blood Adv 7(5):866\u2013874","journal-title":"Blood Adv"},{"issue":"1","key":"5648_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40164-022-00264-3","volume":"11","author":"N Nakamura","year":"2022","unstructured":"Nakamura N, Kasahara S, Kitagawa J et al (2022) A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma. Exp Hematol Oncol 11(1):9","journal-title":"Exp Hematol Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05648-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05648-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05648-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T06:05:30Z","timestamp":1715580330000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05648-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,3]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["5648"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05648-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2024,2,3]]},"assertion":[{"value":"13 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of the First Affiliated Hospital of Zhengzhou University. (protocol code L\/G2022-K013-003, date of approval 5 August 2022).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"Informed consent was obtained from all subjects involved in the study. Written informed consent has been obtained from the patient(s) to publish this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}